ADAD

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 16, 2023

PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and LMI.

Key Points: 
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and LMI.
  • Snow previously held the title of Associate Vice President, Financial Reporting and prior to joining AC Immune worked as a manager at BDO.
  • G&A Expenditures: G&A expenses decreased by CHF 2.1 million for the year ended December 31, 2022 to CHF 15.8 million.
  • AC Immune anticipates that its total cash burn will be in the range of CHF 65 to CHF 75 million for the full year 2023.

AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, October 28, 2022

This bodes well for our wholly owned vaccine ACI-24.060, which targets the two most toxic forms of Abeta, soluble toxic Abeta oligomers and pyroglu-Abeta.

Key Points: 
  • This bodes well for our wholly owned vaccine ACI-24.060, which targets the two most toxic forms of Abeta, soluble toxic Abeta oligomers and pyroglu-Abeta.
  • Because ACI-24.060 is a vaccine, it also has the potential to offer safety, efficacy, and logistical advantages compared to monoclonal antibodies.
  • Interim results are expected around year end 2022 with plans to submit a U.S. Investigational New Drug (IND) application in Q1 2023.
  • Phase 1b safety and immunogenicity data readout in AD and decision to move into DS expected in Q4 2022.

Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC

Retrieved on: 
Tuesday, August 2, 2022

The study evaluated the potential of the anti-amyloid beta antibody crenezumab to slow or prevent Alzheimers disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimers disease.

Key Points: 
  • The study evaluated the potential of the anti-amyloid beta antibody crenezumab to slow or prevent Alzheimers disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimers disease.
  • During the trial, the dose of crenezumab was increased more than seven-fold as knowledge about potential treatment approaches for Alzheimers disease evolved.
  • The Alzheimers Prevention Initiative (API) is an international collaborative formed in 2009 to launch a new era of Alzheimers prevention research.
  • Led by the Banner Alzheimers Institute, the API conducts prevention trials in cognitively healthy people at increased risk for Alzheimers disease.

AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, July 28, 2022

An interim data readout from the Phase 1b portion of the trial in AD is expected in H2 2022.

Key Points: 
  • An interim data readout from the Phase 1b portion of the trial in AD is expected in H2 2022.
  • Announced that AC Immune Co-Founder and CEO Dr. Andrea Pfeifer received the prestigious Aenne Burda Award for Creative Leadership in recognition of her work.
  • Joerg Hornstein, Chief Financial Officer (CFO), will leave AC Immune in the second half of 2022 to pursue a new opportunity.
  • AC Immune is well positioned with two members of the Companys proven Finance Leadership Team who will transition to new roles.

Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting

Retrieved on: 
Thursday, July 28, 2022

Today, the companies Alzheimers portfolio spans investigational medicines for different targets, types and stages of the disease.

Key Points: 
  • Today, the companies Alzheimers portfolio spans investigational medicines for different targets, types and stages of the disease.
  • GRADUATION, an open-label study to evaluate the pharmacodynamic effects of once weekly administration in participants with early Alzheimers disease.
  • Unlike most Alzheimers disease prevention studies, it enrolls people up to 25 years before the disease has started in the brain.
  • Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, stroke, Alzheimers disease, Parkinsons disease and autism spectrum disorder.

Landmark Alzheimer's Prevention Trial Unable to Show Significantly Slower Cognitive Decline in Inherited Form of Disease

Retrieved on: 
Thursday, June 16, 2022

PHOENIX, June 16, 2022 /PRNewswire/ -- A precedent-setting prevention trial in Colombia has found that the investigational medicine crenezumab did not slow or prevent decline in cognition or memory for cognitively healthy people with a rare genetic mutation that causes early-onset Autosomal Dominant Alzheimer's Disease (ADAD).

Key Points: 
  • Carriers of the rare mutation are virtually certain to develop Alzheimer's and tend to become cognitively impaired by around age 44.
  • It also established a precedent-setting commitment to the sharing of trial data and samples with the field to have the greatest possible impact.
  • The API ADAD Trial was the first NIH-supported and potentially label-enabling prevention trial of an investigational Alzheimer's disease-modifying treatment in persons at biological risk for the disease.
  • In addition to several ongoing prevention trials in cognitively unimpaired older adults with biomarker evidence of Alzheimer's disease, other prevention trials are in the planning stages.

AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

Retrieved on: 
Thursday, June 16, 2022

LAUSANNE, Switzerland, June 16, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimer’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer’s disease.

Key Points: 
  • The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimers disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimers disease.
  • We are grateful to all those involved in this landmark study, which will undoubtedly increase the scientific communitys understanding of pre-symptomatic Alzheimers disease and prevention studies conducted in this population.
  • The Alzheimers Prevention Initiative (API) is an international collaborative formed in 2009 to launch a new era of Alzheimers prevention research.
  • Led by the Banner Alzheimers Institute, the API conducts prevention trials in cognitively healthy people at increased risk for Alzheimers disease.

Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

Retrieved on: 
Thursday, June 16, 2022

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimers Institute, today announced results from the Alzheimers Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial.

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimers Institute, today announced results from the Alzheimers Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial.
  • The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimers disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimers disease.
  • Within its Alzheimers pipeline, Genentech is also evaluating the potential of gantenerumab in autosomal dominant Alzheimers disease, as well as for the prevention of sporadic Alzheimers and treatment of early Alzheimers in late stage clinical trials.
  • The Alzheimers Prevention Initiative (API) is an international collaborative formed in 2009 to launch a new era of Alzheimers prevention research.

Ad hoc announcement pursuant to Art. 53 LR: Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease

Retrieved on: 
Friday, October 8, 2021

This Breakthrough Therapy Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous medicine for the treatment of Alzheimers disease with the potential for at-home administration.

Key Points: 
  • This Breakthrough Therapy Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous medicine for the treatment of Alzheimers disease with the potential for at-home administration.
  • This designation for gantenerumab marks the 39th Breakthrough Therapy Designation for Genentechs portfolio of medicines.
  • Gantenerumab is an investigational IgG1 antibody designed to bind to aggregated forms of amyloid beta and remove brain amyloid plaques, a pathological hallmark of Alzheimers disease (AD).
  • GRADUATION, an open-label study to evaluate the pharmacodynamic (PD) effects of once weekly administration of gantenerumab in participants with early AD.